TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25958716

Group type: EXPERIMENTAL
Intervention: Oral chelated zinc with standard treatment (oral prednisolone)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard treatment (oral prednisolone) alone
Number of subjects: 30
Study: 23637065

Group type: EXPERIMENTAL
Intervention: Cocoa with skimmed milk intervention (40 g/day of cocoa powder with 500 mL skimmed milk)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Skimmed milk intervention (500 mL/day of skimmed milk)
Number of subjects: 20
Study: 21068698

Group type: EXPERIMENTAL
Intervention: Thrombomodulin alfa (TM‐α) 0.06 mg·kg for 30 min once daily for 6 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Heparin 8 U·kg·h for 24 h for 6 days
Number of subjects: 80
Study: 19840634

Group type: EXPERIMENTAL
Intervention: Placement of fiber post (DT Light Post) in subgroups post
Number of subjects: 90

Group type: COMPARATOR
Intervention: No post (no root canal retention) in subgroups no post
Number of subjects: 90

Group type: COMPARATOR
Intervention: No post in no-wall group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Placement of fiber post in no-wall group
Number of subjects: 90
Study: 17061634

Group type: EXPERIMENTAL
Intervention: Low dose hydrocortisone supplementation (Group C)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (Group B)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Septic shock patients (Group A)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Relative adrenal insufficiency presence in all groups
Number of subjects: 113
Study: 15557490

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (IFNB-1b) at a dosage of 8 MIU (250 mcg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11741551

Group type: EXPERIMENTAL
Intervention: Intracoronary enalaprilat (50 microg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 22
Study: 9706832

Group type: EXPERIMENTAL
Intervention: 6-week lisinopril treatment
Number of subjects: 6405

Group type: EXPERIMENTAL
Intervention: Predischarge echocardiography
Number of subjects: 6405
Study: 8154278

Group type: EXPERIMENTAL
Intervention: Use of a key and compression of the lag screw
Number of subjects: 153

Group type: COMPARATOR
Intervention: No key and compression of the lag screw
Number of subjects: 153
Study: 3358882

Group type: EXPERIMENTAL
Intervention: Intravenous nifedipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study: 30801373

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 286

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Operative treatment (observational cohort)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Nonoperative treatment (observational cohort)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Operative treatment (overall responder analysis)
Number of subjects: 286
Study: 30170285

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion (0.5 μg/kg per min for 4 hours)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 42
Study: 26313650

Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Gabapentin (1200 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Δ9‐THC (5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Δ9‐THC (15 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Δ9‐THC (30 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Gabapentin and Δ9‐THC (combined)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 24832373

Group type: EXPERIMENTAL
Intervention: Oocyte retrieval by trainees
Number of subjects: 3

Group type: COMPARATOR
Intervention: Senior operator's oocyte retrieval
Number of subjects: 3
Study: 22785500

Group type: EXPERIMENTAL
Intervention: 0.10 mg nor-β-CFT
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.20 mg nor-β-CFT
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.25 mg nor-β-CFT
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.30 mg nor-β-CFT
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (0.10 mg nor-β-CFT)
Number of subjects: 25
Study: 20124183

Group type: EXPERIMENTAL
Intervention: Pertuzumab 420 mg (arm A)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pertuzumab 1,050 mg (arm B)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Overall (both arms)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pertuzumab (both arms)
Number of subjects: 79
Study: 16860874

Group type: EXPERIMENTAL
Intervention: Coping with Depression (CWD) course
Number of subjects: 104

Group type: COMPARATOR
Intervention: Assessment-and-advice-only control group
Number of subjects: 104
Study: 15813473

Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises during pregnancy and puerperium
Number of subjects: 72

Group type: COMPARATOR
Intervention: No pelvic floor exercises
Number of subjects: 72
Study: 10703779

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 401

Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 401
Study: 9493654

Group type: EXPERIMENTAL
Intervention: CFA patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 8450517

Group type: EXPERIMENTAL
Intervention: Fish oil (4.55 g/day of EPA and DHA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily) added to fish oil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nifedipine (20 mg twice daily) added to placebo
Number of subjects: 18
Study: 2429687

Group type: EXPERIMENTAL
Intervention: Citanest with Octapressin (prilocaine 3% with 0.03 i.u./ml. of felypressin)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No anaesthesia
Number of subjects: 50
Study: 3356203

Group type: EXPERIMENTAL
Intervention: Combination of subcutaneous histamine and oral H2-antihistaminics (ranitidine or cimetidine)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-treated patients with similar advanced cancer
Number of subjects: 31
Study: 31740103

Group type: EXPERIMENTAL
Intervention: GAS-based rehabilitation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 120
Study: 31267659

Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 116
Study: 28593326

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.5 µg/kg/h) during surgery and up to 2 hours in the recovery room
Number of subjects: 404

Group type: COMPARATOR
Intervention: Saline placebo infused during surgery and for 2 hours in the recovery room
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Number of subjects: 404

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 404
Study: 25296533

Group type: EXPERIMENTAL
Intervention: Bimatoprost (0.03%)
Number of subjects: 0
Study: 23978160

Group type: EXPERIMENTAL
Intervention: Strategy-adaptation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Strategy training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategy-adaptation training via manual at home
Number of subjects: 0
Study: 21697589

Group type: EXPERIMENTAL
Intervention: Rehabilitation Gaming System (RGS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (intense occupational therapy or non-specific interactive games)
Number of subjects: 8
Study: 19097714

Group type: EXPERIMENTAL
Intervention: Tibolone (1.25 mg/d)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 17046475

Group type: EXPERIMENTAL
Intervention: Long-acting methylprednisolone
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 15232803

Group type: EXPERIMENTAL
Intervention: Remifentanil, 5 microg/kg with glycopyrrolate, 0.2 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fentanyl, 20 microg/kg with glycopyrrolate, 0.2 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Remifentanil and Fentanyl
Number of subjects: 100
Study: 11520836

Group type: EXPERIMENTAL
Intervention: Single infusion of 5 mg/kg liposomal amphotericin B (n=46)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Daily infusions of 1 mg/kg liposomal amphotericin B for five days (n=45)
Number of subjects: 91
Study: 9360753

Group type: EXPERIMENTAL
Intervention: Cytarabine (Cyt)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 8506455

Group type: EXPERIMENTAL
Intervention: 0 hours time in bed
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 4 hours time in bed
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 6 hours time in bed
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 8 hours time in bed
Number of subjects: 32
Study: 3446803

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg oral dose)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30021457

Group type: EXPERIMENTAL
Intervention: ASAP intervention program plus treatment as usual
Number of subjects: 66

Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 66
Study: 28446496

Group type: EXPERIMENTAL
Intervention: mHealth program for 6 months
Number of subjects: 315
Study: 26290106

Group type: EXPERIMENTAL
Intervention: Intravenous 2 μg·kg(‐1)·min(‐1) dopamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Volume-matched saline (placebo)
Number of subjects: 0
Study: 23331565

Group type: EXPERIMENTAL
Intervention: Sublingual allergen-specific immunotherapy (SLIT) with Staloral 300R, Stallergenes, France
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 20599004

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18370886

Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Neutral Writing (NW)
Number of subjects: 24
Study: 16987170

Group type: EXPERIMENTAL
Intervention: Riluzole (100 mg b.i.d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12733091

Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) with flour allergens
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) with alpha-amylase
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Odds ratio for SPT positive to flour or alpha-amylase for asthmatics with onset during bakery work
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Positive predictive value of sensitisation to flour or alpha-amylase
Number of subjects: 65

Group type: COMPARATOR
Intervention: Indices of airway inflammation
Number of subjects: 65
Study: 10631622

Group type: EXPERIMENTAL
Intervention: Repaglinide 1 mg
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Repaglinide 4 mg
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study: 9186283

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU; 120 mg/d orally for 2 months)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 37
Study: 1488998

Group type: EXPERIMENTAL
Intervention: Subcutaneous rHuEPO (150 U/kg/week in three divided doses)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Intravenous rHuEPO (150 U/kg/week in three divided doses)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both groups (subcutaneous and intravenous)
Number of subjects: 128
Study: 3706388

Group type: EXPERIMENTAL
Intervention: Overweight individuals (more than 40 percent overweight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elderly diabetic patients (50 years of age or older)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal weight individuals
Number of subjects: 0
Study: 30460454

Group type: EXPERIMENTAL
Intervention: Prototype marathon racing shoes (NP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nike Zoom Streak 6 (NS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: adidas adizero Adios BOOST 2 (AB)
Number of subjects: 10
Study: 30361406

Group type: EXPERIMENTAL
Intervention: CRP point-of-care tests (POCTs)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control practices (not offered CRP POCT)
Number of subjects: 26
Study: 27870694

Group type: EXPERIMENTAL
Intervention: Intrasession concurrent aerobic before strength training (GAS: n = 39)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Intrasession concurrent aerobic after strength training (GSA: n = 45)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (GC: n = 44; no training program)
Number of subjects: 128
Study: 24468428

Group type: EXPERIMENTAL
Intervention: Fenbendazole treatment group (623 cows)
Number of subjects: 1254

Group type: COMPARATOR
Intervention: Control group (631 cows)
Number of subjects: 1254
Study: 21193295

Group type: EXPERIMENTAL
Intervention: Supervised intensive lifestyle intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Routine lifestyle advice (Control)
Number of subjects: 59
Study: 20430240

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 194

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 194
Study: 17999782

Group type: EXPERIMENTAL
Intervention: Indacaterol 200 microg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Indacaterol 1000 microg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: COMPARATOR
Intervention: Salmeterol 50 microg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Salmabutamol 200 microg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Salmeterol 250 microg
Number of subjects: 39
Study: 15305160

Group type: EXPERIMENTAL
Intervention: Temozolomide plus docetaxel
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Temozolomide plus cisplatin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Temozolomide as single agent
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Temozolomide-based chemotherapy (all groups)
Number of subjects: 25
Study: 11641669

Group type: EXPERIMENTAL
Intervention: Oxytocin administration before placental delivery
Number of subjects: 1486

Group type: COMPARATOR
Intervention: Oxytocin administration after placental delivery
Number of subjects: 1486
Study: 9852693

Group type: EXPERIMENTAL
Intervention: Bolus administration of mexiletine 2 mg.kg‐1
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bolus administration of mexiletine 1 mg.kg‐1 with continuous administration of 1 mg.kg‐1.hr‐1 for 75 minutes
Number of subjects: 28

Group type: COMPARATOR
Intervention: No mexiletine administration
Number of subjects: 28
Study: 8276350

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock‐wave lithotripsy followed by methyl tert‐butyl ether dissolution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Methyl tert‐butyl ether alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock‐wave lithotripsy and methyl tert‐butyl ether dissolution
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock‐wave lithotripsy and methyl tert‐butyl ether
Number of subjects: 50
Study: 2609736

Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glucagon
Number of subjects: 60
Study: 30760509

Group type: EXPERIMENTAL
Intervention: Palivizumab (15 mg/kg)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 420
Study: 28099357

Group type: EXPERIMENTAL
Intervention: bilayered negative pressure wound therapy (b‐NPWT) applied to thigh incision for 5 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Traditional surgical pads applied to control thigh and control shank incisions
Number of subjects: 72
Study: 26581899

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sedentary Behavior (SB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory Fitness (CRF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fatigue, Age, Fat Mass, Cancer Treatment Status
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CRF
Number of subjects: 60
Study: 24152215

Group type: EXPERIMENTAL
Intervention: cFIR neck device for 1 week
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (sham-treatment) group with inert neck device for 1 week
Number of subjects: 48
Study: 22265220

Group type: EXPERIMENTAL
Intervention: Intraperitoneal irrigation with a solution of 240 mg gentamicin and 600 mg clindamycin
Number of subjects: 103

Group type: COMPARATOR
Intervention: Intra-abdominal irrigation with normal saline
Number of subjects: 103
Study: 21126374

Group type: EXPERIMENTAL
Intervention: Consideration of extremely good health state descriptors (Description-A)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Consideration of extremely poor health state descriptors (Description-B)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Consideration of best health VAS anchor
Number of subjects: 151
Study: 17402993

Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha2a (40 kDa) 180 microg/week plus ribavirin 1000/1200 mg/day for 48 weeks
Number of subjects: 475
Study: 15806621

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive randomization procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-stage chemotherapy
Number of subjects: 0
Study: 12096303

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using photosensitizers activated by light
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of PDT with other established modalities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of photosensitizers for endoscopic diagnosis and treatment guidance
Number of subjects: 0
Study: 9802531

Group type: EXPERIMENTAL
Intervention: Alcohol (0.56 g/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9593798

Group type: EXPERIMENTAL
Intervention: Capsaicin cream (1.5 g, 1%) applied for 15 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo cream applied for 15 min
Number of subjects: 10
Study: 1897303

Group type: EXPERIMENTAL
Intervention: PFHSP70 antigen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total schizont antigens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-responsiveness to PFHSP70
Number of subjects: 0
Study: 6614638

Group type: EXPERIMENTAL
Intervention: H2SO4 and NH4HSO4 at 1,000 micrograms/m3
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: H2SO4 at 450 micrograms/m3
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sodium chloride (NaCl) aerosol
Number of subjects: 17
Study: 31189338

Group type: EXPERIMENTAL
Intervention: Telephone Interpersonal Counseling (TIPC)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Supportive Health Education (SHE)
Number of subjects: 241
Study: 30528315

Group type: EXPERIMENTAL
Intervention: Cabozantinib 100 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Entire cohort (Cabozantinib and Placebo)
Number of subjects: 60
Study: 28935146

Group type: EXPERIMENTAL
Intervention: Dark chocolate (65 g, 2148 mg polyphenols)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo chocolate (without polyphenols)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Mate tea (3 g, 107 mg total phenols, 84.24 mg chlorogenic acid)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo mate (without polyphenols)
Number of subjects: 92
Study: 26794189

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer liner (Glass Liner II)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No lining (control group)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both interventions (lined and unlined)
Number of subjects: 39
Study: 26813555

Group type: EXPERIMENTAL
Intervention: Long-time SBPV group (2,279 participants)
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: Short-time SBPV group (1,636 participants)
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: Long- plus short-time SBPV group (1,632 participants)
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: Day time SBPV increase
Number of subjects: 2464
Study: 24152796

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 38
Study: 21802921

Group type: EXPERIMENTAL
Intervention: Ivy leaves soft extract
Number of subjects: 590

Group type: COMPARATOR
Intervention: Other ivy leaves extract
Number of subjects: 590
Study: 18806764

Group type: EXPERIMENTAL
Intervention: LDL apheresis (LA) combined with conventional therapy (CT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional therapy (CT) only
Number of subjects: 20
Study: 16394045

Group type: EXPERIMENTAL
Intervention: IVIG plus prednisone
Number of subjects: 78

Group type: COMPARATOR
Intervention: IVIG alone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Fetal blood sampling procedures
Number of subjects: 78
Study: 15161800

Group type: EXPERIMENTAL
Intervention: 32-33 split proinsulin
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Intact proinsulin
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Early insulin response (EIR)
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity index (S(i))
Number of subjects: 667
Study: 12968768

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0
Study: 10538481

Group type: EXPERIMENTAL
Intervention: Spiral computed tomography (spiral CT) for lung cancer screening
Number of subjects: 0
Study: 7659484

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Whole‐cell vaccines
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: One vaccine without detectable FIM
Number of subjects: 15
Study: 2695280

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg bd (n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 12